Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28583813 | 0.91 | SREBF2 (0.47) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| SCHEMBL23168284 | 0.84 | SREBF2 (0.47) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| Acetic Acid SCHEMBL28084883 | 0.83 | SREBF2 (0.46) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| SCHEMBL30955414 | 0.83 | ATR (0.49) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| SCHEMBL28916940 | 0.82 | SREBF2 (0.46) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| SCHEMBL30530884 | 0.81 | SREBF2 (0.45) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| SCHEMBL13387936 | 0.80 | SREBF2 (0.46) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| SCHEMBL30955481 | 0.80 | SREBF2 (0.44) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| SCHEMBL28152360 | 0.80 | SREBF2 (0.44) | SREBF2CYP17A1ATRAURKARPS6KB1 | |
| SCHEMBL30955460 | 0.79 | SREBF2 (0.46) | SREBF2CYP17A1ATRAURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177186-B1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | AVENTIS PHARMA LTD (GB) | 2004-03-31 | — | — | EP | disclosed |
| US-6620832-B2 | Inhibitor of alpha 4 beta 1 mediated cell adhesion; treatment for asthma and antiinflammatory | AVENTIS PHARMA LTD. (GB) | 2003-09-16 | — | — | US | disclosed |
| US-20020082255-A1 | Substituted ureas | AVENTIS PHARMA LIMITED (GB) | 2002-06-27 | — | — | US | disclosed |
| EP-1177186-A1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | Aventis Pharma Limited (GB) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000068223-A1 | UREAS AND THEIR USE AS CELL ADHESION MODULATORS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082255-A1 | Substituted ureas | VCAM1, ITGA1, ITGB1 | SREBF2 4139/4885CYP17A1 1708/4885ATR 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.